Current Cardiology Reports

, Volume 6, Issue 4, pp 253–258

Markers to define ischemia: Are they ready for prime time use in patients with acute coronary syndromes?

  • Jesse Adams
Article

Abstract

Optimal treatment of patients who present with chest pain is predicated on accurate identification of those patients with a cardiac etiology of their discomfort. Serial troponins and electrocardiograms are very sensitive for the detection of myocardial infarction but they are insensitive for the detection of ischemia. There are many analytes that are being actively evaluated for routine use to facilitate the identification of patients with myocardial ischemia. At present, only one assay is US Food and Drug Administration-approved for the exclusion of ischemia; many other analytes are under clinical evaluation and are briefly reviewed. At present, none of these analytes are yet appropriate for routine clinical use.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Hamm CW, Braunwald E: A classification of unstable angina revisited. Circulation 2000, 102:118–122. An excellent review of the pertinent etiologic biology of ACS; necessary to understand the application of markers.PubMedGoogle Scholar
  2. 2.
    Braunwald E, Antman EM, Beasley JW, et al.: ACC/AHA guidelines for the management of patients with unstable angina and non- ST segment elevation myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients with Unstable Angina). J Am Coll Cardiol 2000, 36:970–1062. The current consensus document for the accepted evaluation and treatment of patients who present with ACS.PubMedCrossRefGoogle Scholar
  3. 3.
    Pope JH, Selker HP: Diagnosis of acute cardiac ischemia. Emerg Med Clin North Am 2003, 21:27–59.PubMedCrossRefGoogle Scholar
  4. 4.
    Selker HP, Zalenski RJ, Antman EM, et al.: An evaluation of technologies for identifying acute cardiac ischemia in the emergency department: a report from a National Heart Attack Alert Program working group. Ann Emerg Med 1997, 29:13–87.PubMedCrossRefGoogle Scholar
  5. 5.
    Apple FS, Quist HE, Doyle PJ, et al.: Plasma 99th percentile reference limits for cardiac troponin and creatine kinase MB mass for use with European Society of Cardiology/American College of Cardiology consensus recommendations. Clin Chem 2003, 49:1331–1336. The overview of the best contemporary cutpoints to use for troponin testing.PubMedCrossRefGoogle Scholar
  6. 6.
    Libby P, Ridker PM, Maseri A: Inflammation and atherosclerosis. Circulation 2002, 105:1135–1143.PubMedCrossRefGoogle Scholar
  7. 7.
    Liuzzo G, Biasucci LM, Rebuzzi AG, et al.: Plasma protein acute-phase response in unstable angina is not induced by ischemic injury. Circulation 1996, 94:2373–2380.PubMedGoogle Scholar
  8. 8.
    Sabatine MS, Morrow DA, de Lemos JA, et al.: Multimarker approach to risk stratification in non-ST elevation acute coronary syndromes: simultaneous assessment of troponin I, C-reactive protein, and B-type natriuretic peptide. Circulation 2002, 105:1760–1763.PubMedCrossRefGoogle Scholar
  9. 9.
    Myocardial infarction redefined: a consensus document of the Joint European Society of Cardiology/American College of Cardiology Committee for the Redefinition of Myocardial Infarction. J Am Coll Cardiol 2000, 36:959–969. Myocardial infarction redefined for the current diagnostic age; this is the current paradigm for marker diagnostics.Google Scholar
  10. 10.
    Antman EM, Tanasijevic MJ, Thompson B, et al.: Cardiacspecific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes. N Engl J Med 1996, 335:1342–1349.PubMedCrossRefGoogle Scholar
  11. 11.
    Jaffe AS: Testing the wrong hypothesis: the failure to recognize the limitations of troponin testing. J Am Coll Cardiol 2001, 38:999–1001. An excellent overview of the limitation of diagnostic assays. The issues raised here are critical for assessment of these relatively scantily evaluated markers of ischemia.PubMedCrossRefGoogle Scholar
  12. 12.
    McDonough JL, Labugger R, Van Eyk JE: Prepare to meet your markers: making the most of troponin degradation. In Markers in Cardiology: Current and Future Clinical Applications. Edited by Adams JE, Apple FS, Jaffe AS, Wu AHB. Armonk, NJ: Futura; 2001:13–21.Google Scholar
  13. 13.
    Feldman L, Rouleau C: Troponin I inhibits endothelial cell proliferation by interaction with the cell’s bFGF receptor. Microvasc Res 2002, 63:41–49.PubMedCrossRefGoogle Scholar
  14. 14.
    Moses MA, Wiederschain D, Wu I, et al.: Troponin I is present in human cartilage and inhibits angiogenesis. Proc Natl Acad Sci U S A 1999, 96:2645–2650.PubMedCrossRefGoogle Scholar
  15. 15.
    Schonbeck U, Varo N, Libby P, et al.: Soluble CD40L and cardiovascular risk in women. Circulation 2001, 104:2266–2268.PubMedGoogle Scholar
  16. 16.
    Varo N, de Lemos JA, Libby P, et al.: Soluble CD40L risk prediction after acute coronary syndromes. Circulation 2003, 108:1049–1052.PubMedCrossRefGoogle Scholar
  17. 17.
    Heeschen C, Dimmler S, Hamm CW, et al.: Soluble CD40 ligand in acute coronary syndromes. N Engl J Med 2003, 348:1104–1111.PubMedCrossRefGoogle Scholar
  18. 18.
    Danne O, Mockel M, Lueders C, et al.: Prognostic implications of elevated whole blood choline levels in acute coronary syndromes. Am J Cardiol 2003, 91:1060–1067.PubMedCrossRefGoogle Scholar
  19. 19.
    Blankenberg S, Rupprecht HJ, Bickel C, et al.: Glutathione peroxidase 1 activity and cardiovascular events in patients with coronary artery disease. N Engl J Med 2003, 349:1605–1613.PubMedCrossRefGoogle Scholar
  20. 20.
    Singa MK, Roy D, Gaze DC, et al.: Role of “ischemia modified albumin,” a new biochemical marker of myocardial ischemia, in the early diagnosis of acute coronary artery syndromes. Emerg Med J 2004, 21:29–34. This article is the best assessment yet of the only FDA-approved assay, IMA, for the exclusion of ischemia.CrossRefGoogle Scholar
  21. 21.
    Brennan ML, Penn MS, Van Lente F, et al.: Prognostic value of myeloperoxidase in patients with chest pain. N Engl J Med 2003, 349:1595–1604.PubMedCrossRefGoogle Scholar
  22. 22.
    Baldus S, Heeschen C, Meinertz T, et al., for the CAPTURE investigators: Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes. Circulation 2003, 108:1440–1445.PubMedCrossRefGoogle Scholar
  23. 23.
    James SK, Lindahl B, Siegbahn A, et al.: N-terminal pro-brain natriuretic peptide and other risk markers for the separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery disease. Circulation 2003, 108:275–281.PubMedCrossRefGoogle Scholar
  24. 24.
    Morrow DA, Braunwald E: Future of biomarkers in acute coronary syndromes. Circulation 2003, 108:250–252. An excellent review of the potential of application of a multimarker strategy for the detection of ACS.PubMedCrossRefGoogle Scholar
  25. 25.
    Lund J, Qin QP, Ilva T, et al.: Circulating pregnancy-associated plasma protein a predicts outcome in patients with acute coronary syndrome but no troponin I elevation. Circulation 2003, 108:1924–1926.PubMedCrossRefGoogle Scholar
  26. 26.
    Kleinfeld AM, Kleinfeld KJ, Adams JE: Serum levels of unbound free fatty acids reveal high sensitivity for early detection of acute myocardial infarction in patient samples from the TIMI II trial. J Am Coll Cardiol 2002, 39:413A.CrossRefGoogle Scholar
  27. 27.
    Adams JE, Kleinfeld A, Roe M, et al.: Measurement of levels of unbound free fatty acid allows the early identification of patients with acute coronary syndromes [abstract]. Circulation 2002,105:1–324.CrossRefGoogle Scholar

Copyright information

© Current Science Inc. 2004

Authors and Affiliations

  • Jesse Adams
    • 1
  1. 1.Division of CardiologyUniversity of LouisvilleLouisvilleUSA

Personalised recommendations